多发性硬化症的治疗进展。
Advances in the Treatment of Multiple Sclerosis.
机构信息
Mellen Center U-10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Mellen Center U-10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
出版信息
Neurol Clin. 2021 Feb;39(1):21-33. doi: 10.1016/j.ncl.2020.09.002. Epub 2020 Nov 7.
Abstract
Multiple sclerosis is a relatively common, immune-mediated neurologic disease of the central nervous system that can cause significant disability and lead to reduced quality of life. There are several currently approved disease-modifying therapies, and more in the pipeline being developed and tested. As the field learns more about the pathophysiology and natural course of the disease, the treatment approaches are also being investigated. This article reviews data on available treatments along with a discussion of future treatment targets under investigation.
摘要
多发性硬化症是一种相对常见的中枢神经系统免疫介导性疾病，可导致严重残疾并降低生活质量。目前有几种已批准的疾病修正治疗方法，还有更多正在开发和测试中。随着该领域对疾病的病理生理学和自然病程的了解不断增加，治疗方法也在进行研究。本文回顾了现有治疗方法的数据，并讨论了正在研究的未来治疗靶点。
相似文献
1
Advances in the Treatment of Multiple Sclerosis.多发性硬化症的治疗进展。
Neurol Clin. 2021 Feb;39(1):21-33. doi: 10.1016/j.ncl.2020.09.002. Epub 2020 Nov 7.
2
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?迈向多发性硬化症合理治疗方法的发展：未来有什么新进展？
Ann Neurol. 2007 Oct;62(4):314-26. doi: 10.1002/ana.21289.
3
Approaches to neuroprotective strategies in multiple sclerosis.多发性硬化症的神经保护策略方法。
Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5.
4
Linkage between immunomodulation, neuroprotection and neurogenesis.免疫调节、神经保护与神经发生之间的联系。
Drug News Perspect. 2009 Jul-Aug;22(6):301-12. doi: 10.1358/dnp.2009.22.6.1395253.
5
Mode of action and clinical studies with fumarates in multiple sclerosis.富马酸盐治疗多发性硬化症的作用机制及临床研究
Exp Neurol. 2014 Dec;262 Pt A:52-6. doi: 10.1016/j.expneurol.2014.02.015. Epub 2014 Feb 22.
6
New therapeutic approaches for multiple sclerosis.多发性硬化症的新治疗方法。
Annu Rev Med. 2007;58:417-32. doi: 10.1146/annurev.med.58.071105.111552.
7
MS pipeline flowing, but niche remains for neuroprotection.多发性硬化症治疗流程正在推进，但神经保护领域仍有空间。
Nat Med. 2011 Nov 7;17(11):1327. doi: 10.1038/nm1111-1327.
8
Emerging disease modifying therapies for multiple sclerosis.用于多发性硬化症的新型疾病修正疗法。
Expert Opin Emerg Drugs. 2003 May;8(1):145-61. doi: 10.1517/14728214.8.1.145.
9
Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design.多发性硬化症中的神经保护：治疗策略与临床试验设计
Curr Opin Neurol. 2006 Jun;19(3):255-9. doi: 10.1097/01.wco.0000227034.85576.16.
10
[Multiple sclerosis at the time of world-wide use of disease modifying treatment].[全球使用疾病修正治疗时的多发性硬化症]
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):4-9.
引用本文的文献
1
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.多发性硬化症高效疾病修正疗法的应用：专家德尔菲共识推荐意见
J Neurol. 2025 Aug 10;272(9):565. doi: 10.1007/s00415-025-13293-9.
2
Personalized therapy in multiple sclerosis: an Italian Delphi consensus.多发性硬化症的个性化治疗：意大利德尔菲共识
J Neurol. 2025 May 27;272(6):428. doi: 10.1007/s00415-025-13173-2.
3
Exploring the Perspectives of Healthcare Consumers Towards the Integration of Nutrition in Routine Multiple Sclerosis Care: A Qualitative Study.探索医疗保健消费者对将营养纳入常规多发性硬化症护理的看法：一项定性研究。
J Hum Nutr Diet. 2025 Apr;38(2):e70042. doi: 10.1111/jhn.70042.
4
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.间充质干细胞治疗多发性硬化症的最新进展：临床应用与挑战
Front Cell Dev Biol. 2025 Feb 3;13:1517369. doi: 10.3389/fcell.2025.1517369. eCollection 2025.
5
Overview of emerging therapies for demyelinating diseases.脱髓鞘疾病新兴疗法概述
World J Clin Cases. 2024 Oct 26;12(30):6361-6373. doi: 10.12998/wjcc.v12.i30.6361.
6
Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.机器人康复对多发性硬化症患者步态和平衡的有效性：系统评价。
J Neurol. 2024 Nov;271(11):7141-7155. doi: 10.1007/s00415-024-12715-4. Epub 2024 Oct 10.
7
Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis.患者诱导多能干细胞模型揭示多发性硬化症中的神经胶质固有表型。
Cell Stem Cell. 2024 Nov 7;31(11):1701-1713.e8. doi: 10.1016/j.stem.2024.08.002. Epub 2024 Aug 26.
8
Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review.用于多发性硬化症研究的芯片上神经炎症：一篇综述
Ann Med Surg (Lond). 2024 May 28;86(7):4053-4059. doi: 10.1097/MS9.0000000000002231. eCollection 2024 Jul.
9
Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment.多发性硬化症注射疗法和口服疗法的依从性、持续性、换药情况及成本：6年治疗的真实生活分析
Hosp Pharm. 2024 Aug;59(4):476-484. doi: 10.1177/00185787241232615. Epub 2024 Feb 15.
10
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.早期在美国多发性硬化症中使用高效疗法：益处、障碍和鼓励采用的策略。
J Neurol. 2024 Jun;271(6):3116-3130. doi: 10.1007/s00415-024-12305-4. Epub 2024 Apr 14.
本文引用的文献
1
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.三种神经保护药物在继发进展型多发性硬化症（MS-SMART）中的疗效：一项 2b 期、多臂、双盲、随机安慰剂对照试验。
Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22.
2
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.在复发缓解型多发性硬化症患者中，与富马酸二甲酯相比，富马酸二罗西美显示出更好的胃肠道耐受性：随机、双盲、III期EVOLVE-MS-2研究结果。
CNS Drugs. 2020 Feb;34(2):185-196. doi: 10.1007/s40263-020-00700-0.
3
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.富马酸二甲酯（DRF）治疗复发缓解型多发性硬化症患者的安全性和有效性：III 期 EVOLVE-MS-1 研究的中期结果。
Mult Scler. 2020 Nov;26(13):1729-1739. doi: 10.1177/1352458519881761. Epub 2019 Nov 4.
4
Progressive multiple sclerosis: latest therapeutic developments and future directions.进展性多发性硬化症：最新治疗进展与未来方向
Ther Adv Neurol Disord. 2019 Sep 25;12:1756286419878323. doi: 10.1177/1756286419878323. eCollection 2019.
5
Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells.二甲双胍通过激活衰老的干细胞来恢复中枢神经系统的髓鞘再生能力。
Cell Stem Cell. 2019 Oct 3;25(4):473-485.e8. doi: 10.1016/j.stem.2019.08.015.
6
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.多发性硬化症患者使用延长间隔剂量可降低纳他珠单抗相关进行性多灶性脑白质病的风险。
Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.
7
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.奥扎莫德与干扰素β-1a 在复发型多发性硬化症（RADIANCE）中的安全性和疗效：一项多中心、随机、24 个月、3 期临床试验。
Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.
8
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.奥扎莫德与干扰素β-1a 在复发型多发性硬化症中的安全性和疗效（SUNBEAM）：一项多中心、随机、至少 12 个月、3 期临床试验。
Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.
9
The potential use of mesenchymal stem cells for the treatment of multiple sclerosis.间充质干细胞在多发性硬化症治疗中的潜在应用。
Life Sci. 2019 Oct 15;235:116830. doi: 10.1016/j.lfs.2019.116830. Epub 2019 Sep 2.
10
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.进展性多发性硬化症：从病理生理学到治疗策略。
Nat Rev Drug Discov. 2019 Dec;18(12):905-922. doi: 10.1038/s41573-019-0035-2. Epub 2019 Aug 9.
Zotero 插件